What This Site Is
Clinic GHK-Cu is an independent editorial project that publishes summaries of the peer-reviewed research literature on GHK-Cu (Copper Tripeptide-1). We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.
The 'clinic' in our name is a reading-room framing — the position we occupy relative to the literature, not a claim about services offered. Clinic GHK-Cu is a structured editorial digest of what the published research has measured, not a source of prescriptions, consultations, or treatment guidance. No content on this site should be interpreted as medical advice.
GHK-Cu (Copper Tripeptide-1) has been studied across five decades of peer-reviewed research beginning with Loren Pickart's 1973 isolation from human plasma. The literature spans collagen stimulation,[1] gene expression,[4] hair follicle biology,[7] wound healing,[13][16] and pharmacokinetics.[18] This site documents that literature — every claim cited to its published source.
We do not recommend doses or administration routes for human use. We do not evaluate products, vendors, or formulations. We do not represent that any compound discussed here is approved, effective, or safe for human therapeutic use beyond what the cited literature states.
Editorial Standards
Every quantitative claim on this site links to a numbered citation in the references index. Citations are drawn from PubMed, PubMed Central, ClinicalTrials.gov, and peer-reviewed journal sources. We prioritize human clinical data where available; where clinical data is absent, we describe preclinical (rodent, cell model) findings and explicitly note the distinction.
We describe dose-response data in the format: 'studied at X [unit] in [species] via [route].' We do not reframe this as personal dosing guidance. We do not name competing branded drug products by trademark. We do not use language that implies medical endorsement.
GHK-Cu is not FDA-approved as a drug for any indication. Copper Tripeptide-1 is a legal cosmetic ingredient in the US, EU, and UK. Injectable GHK-Cu is outside FDA-approved indications. These regulatory facts are stated plainly on the dosage and FAQ pages of this site.
EDITORIAL VOICE
This site is written in a clinical-but-approachable voice: precise about what the research shows, honest about what it doesn't show, and accessible to readers who are not scientists. Every section distinguishes between in vitro findings, animal model findings, and human clinical data. We describe the evidence; we do not interpret it as guidance.
For frequently asked questions about GHK-Cu, GHK-Cu mechanism of action, and peer-reviewed references, use the navigation above.